Serving the Society Since 1986
Advanced Search
Volume 38 Issue 6
December 2023
    Citation: Lu Wang, Xiaoqing Zeng, Zida Wang, Ling Fang, Jia Liu. Recent advances in understanding T cell activation and exhaustion during HBV infection .VIROLOGICA SINICA, 2023, 38(6) : 851-859.  http://dx.doi.org/10.1016/j.virs.2023.10.007
    shu

    Recent advances in understanding T cell activation and exhaustion during HBV infection

    • a. Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China;

    • b. Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, 430022, China;

    • c. Central Sterile Supply Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    • Chronic hepatitis B virus (HBV) infection remains a major public health concern globally, and T cell responses are widely believed to play a pivotal role in mediating HBV clearance. Accordingly, research on the characteristics of HBV-specific T cell responses, from activation to exhaustion, has advanced rapidly. Here, we summarize recent developments in characterizing T cell immunity in HBV infection by reviewing basic and clinical research published in the last five years. We provide a comprehensive summary of the mechanisms that induce effective anti-HBV T cell immunity, as well as the latest developments in understanding T cell dysfunction in chronic HBV infection. Furthermore, we briefly discuss current novel treatment strategies aimed at restoring anti-HBV T cell responses.
    • 加载中

      1. Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H. E., Roelli, P., Utzschneider, D. T., von Hoesslin, M., Cullen, J. G., Fan, Y., Eisenberg, V., Wohlleber, D., Steiger, K., Merkler, D., Delorenzi, M., Knolle, P. A., Cohen, C. J., Thimme, R., Youngblood, B., Zehn, D. 2019. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265-269.

      2. Aliabadi, E., Urbanek-Quaing, M., Maasoumy, B., Bremer, B., Grasshoff, M., Li, Y., Niehaus, C. E., Wedemeyer, H., Kraft, A., Cornberg, M. 2022. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut 71, 2300-2312.

      3. Asabe, S., Wieland, S. F., Chattopadhyay, P. K., Roederer, M., Engle, R. E., Purcell, R. H., Chisari, F. V. 2009. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 83, 9652-62.

      4. Beckebaum, S., Cicinnati, V. R., Zhang, X., Ferencik, S., Frilling, A., Grosse-Wilde, H., Broelsch, C. E., Gerken, G. 2003. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 re-sponse in vitro: mechanisms for viral immune escape. Immunology 109, 487-95.

      5. Benechet, A. P., De Simone, G., Di Lucia, P., Cilenti, F., Barbiera, G., Le Bert, N., Fumagalli, V., Lusito, E., Moalli, F., Bianchessi, V., Andreata, F., Zordan, P., Bono, E., Giustini, L., Bonilla, W. V., Bleriot, C., Kunasegaran, K., Gonzalez-Aseguinolaza, G., Pinschewer, D. D., Kennedy, P., Naldini, L., Kuka, M., Ginhoux, F., Cantore, A., Ber-toletti, A., Ostuni, R., Guidotti, L. G., Iannacone, M. 2019. Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming. Nature 574, 200-205.

      6. Bertoletti, A., Ferrari, C. 2016. Adaptive immunity in HBV infection. J Hepatol 64, S71-S83.

      7. Bohne, F., Chmielewski, M., Ebert, G., Wiegmann, K., Kurschner, T., Schulze, A., Urban, S., Kronke, M., Abken, H., Protzer, U. 2008. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134, 239-47.

      8. Cova, L. 2017. Present and future DNA vaccines for chronic hepatitis B treatment. Expert Opin Biol Ther 17, 185-195.

      9. Cui, D., Jiang, D., Yan, C., Liu, X., Lv, Y., Xie, J., Chen, Y. 2022. Immune Checkpoint Molecules Expressed on CD4(+) T Cell Subsets in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative. Front Microbiol 13, 887408.

      10. De Simone, G., Andreata, F., Bleriot, C., Fumagalli, V., Laura, C., Garcia-Manteiga, J. M., Di Lucia, P., Gilotto, S., Ficht, X., De Ponti, F. F., Bono, E. B., Giustini, L., Ambrosi, G., Mainetti, M., Zordan, P., Benechet, A. P., Rava, M., Chakarov, S., Moalli, F., Bajenoff, M., Guidotti, L. G., Ginhoux, F., Iannacone, M. 2021. Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming. Immunity 54, 2089-2100.e8.

      11. Dong, Y., Li, X., Yu, Y., Lv, F., Chen, Y. 2020. JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B. Life Sci 252, 117663.

      12. Du B, Teng, J., Yin, R., Tian, Y., Jiang, T., Du Y, Cai, W. 2021. Increased Circulating T Follicular Helper Cells Induced via IL-12/21 in Patients With Acute on Chronic Hepatitis B Liver Failure. Front Immunol 12, 641362.

      13. Fanning, G. C., Zoulim, F., Hou, J., Bertoletti, A. 2019. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov 18, 827-844.

      14. Ferrando-Martinez, S., Snell, B. A., Lino, E., Gehring, A. J., Feld, J., Janssen, H., Robbins, S. H. 2021. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection. Front Im-munol 12, 648420.

      15. Fisicaro, P., Barili, V., Rossi, M., Montali, I., Vecchi, A., Acerbi, G., Laccabue, D., Zecca, A., Penna, A., Missale, G., Ferrari, C., Boni, C. 2020. Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. Front Immunol 11, 849.

      16. Fisicaro, P., Valdatta, C., Massari, M., Loggi, E., Biasini, E., Sacchelli, L., Cavallo, M. C., Silini, E. M., Andreone, P., Missale, G., Ferrari, C. 2010. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138, 682-93, 693.e1-4.

      17. Fumagalli, V., Venzin, V., Di Lucia, P., Moalli, F., Ficht, X., Ambrosi, G., Giustini, L., Andreata, F., Grillo, M., Magini, D., Rava, M., Friedrich, C., Fontenot, J. D., Bousso, P., Gilmore, S. A., Khan, S., Baca, M., Vivier, E., Gasteiger, G., Kuka, M., Guidotti, L. G., Iannacone, M. 2022. Group 1 ILCs regulate T cell-mediated liver immunopathology by controlling local IL-2 availability. Sci Immunol 7, eabi6112.

      18. Gane, E., Verdon, D. J., Brooks, A. E., Gaggar, A., Nguyen, A. H., Subramanian, G. M., Schwabe, C., Dunbar, P. R. 2019. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol 71, 900-907.

      19. Hakim, M. S., Rahmadika, N., Jariah, R. 2020. Expressions of inhibitory checkpoint molecules in acute and chronic HBV and HCV infections: Implications for therapeutic monitoring and personalized therapy. Rev Med Virol 30, e2094.

      20. Heim, K., Binder, B., Sagar, Wieland, D., Hensel, N., Llewellyn-Lacey, S., Gostick, E., Price, D. A., Emmerich, F., Vingerhoet, H., Kraft, A., Cornberg, M., Boettler, T., Neumann-Haefelin, C., Zehn, D., Bengsch, B., Hofmann, M., Thimme, R. 2020. TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection. Gut.

      21. Hoogeveen, R. C., Dijkstra, S., Bartsch, L. M., Drescher, H. K., Aneja, J., Robidoux, M. P., Cheney, J. A., Timm, J., Gehring, A., de Sousa, P., Ximenez, L., Peliganga, L. B., Pitts, A., Evans, F. B., Boonstra, A., Kim, A. Y., Lewis-Ximenez, L. L., Lauer, G. M. 2022. Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen(+) infection. J Hepatol 77, 1276-1286.

      22. Hoogeveen, R. C., Robidoux, M. P., Schwarz, T., Heydmann, L., Cheney, J. A., Kvistad, D., Aneja, J., Melgaco, J. G., Fernandes, C. A., Chung, R. T., Boonstra, A., Kim, A. Y., Baumert, T. F., Timm, J., Lewis-Ximenez, L. L., Tonnerre, P., Lauer, G. M. 2019. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut 68, 893-904.

      23. Huang, S., Zou, S., Chen, M., Gao, X., Chen, L., Yang, X., Yu, Q., Zhao, X., Du Y, Yang, X., Lin, Y., Wang, B., Lu, Y., Liu, J., Zheng, X., Gong, F., Lu, M., Yang, D., Wu, J. 2018. Local Stimulation of Liver Sinusoidal Endothelial Cells with a NOD1 Agonist Activates T Cells and Suppresses Hepatitis B Virus Replication in Mice. J Immunol 200, 3170-3179.

      24. Iannacone, M., Guidotti, L. G. 2022. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Im-munol 22, 19-32.

      25. Jarczak, D., Nierhaus, A. 2022. Cytokine Storm-Definition, Causes, and Implications. Int J Mol Sci 23.

      26. Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., Attanasio, J., Yan, P., George, S. M., Bengsch, B., Staupe, R. P., Donahue, G., Xu, W., Amaravadi, R. K., Xu, X., Karakousis, G. C., Mitchell, T. C., Schuchter, L. M., Kaye, J., Berger, S. L., Wherry, E. J. 2019. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature 571, 211-218.

      27. Khanam, A., Ayithan, N., Tang, L., Poonia, B., Kottilil, S. 2020. IL-21-Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B. Front Immunol 11, 599648.

      28. Klopp, A., Schreiber, S., Kosinska, A. D., Pule, M., Protzer, U., Wisskirchen, K. 2021. Depletion of T cells via In-ducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B. Front Immunol 12, 734246.

      29. Kosinska, A. D., Festag, J., Muck-Hausl, M., Festag, M. M., Asen, T., Protzer, U. 2021. Immunogenicity and Anti-viral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection. Vaccines (Basel) 9.

      30. Krebs, K., Bottinger, N., Huang, L. R., Chmielewski, M., Arzberger, S., Gasteiger, G., Jager, C., Schmitt, E., Bohne, F., Aichler, M., Uckert, W., Abken, H., Heikenwalder, M., Knolle, P., Protzer, U. 2013. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145, 456-65.

      31. Kruse, R. L., Shum, T., Tashiro, H., Barzi, M., Yi, Z., Whitten-Bauer, C., Legras, X., Bissig-Choisat, B., Garaigorta, U., Gottschalk, S., Bissig, K. D. 2018. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy 20, 697-705.

      32. Kumar, B. V., Connors, T. J., Farber, D. L. 2018. Human T Cell Development, Localization, and Function through-out Life. Immunity 48, 202-213.

      33. Le Bert, N., Gill, U. S., Hong, M., Kunasegaran, K., Tan, D., Ahmad, R., Cheng, Y., Dutertre, C. A., Heinecke, A., Rivino, L., Tan, A., Hansi, N. K., Zhang, M., Xi, S., Chong, Y., Pflanz, S., Newell, E. W., Kennedy, P., Bertoletti, A. 2020. Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. Gastroenterology 159, 652-664.

      34. Lee, B. T., Fiel, M. I., Schiano, T. D. 2021. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. J Hepatol 75, 1203-1216.

      35. Li, C., Yu, T., Shi, X., Yu, J. 2022. Interleukin-33 Reinvigorates Antiviral Function of Viral-Specific CD8(+) T Cells in Chronic Hepatitis B Virus Infection. Viral Immunol 35, 41-49.

      36. Li, Y., Tang, L., Guo, L., Chen, C., Gu, S., Zhou, Y., Ye, G., Li, X., Wang, W., Liao, X., Wang, Y., Peng, X., Liu, G., Zhang, X., Sun, J., Peng, J., Hou, J. 2020. CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection. J Hepatol 72, 420-430.

      37. Liu, F., Zhang, S., Wong, D. K., Huang, F. Y., Cheung, K. S., Mak, L. Y., Fung, J., Yuen, M. F., Seto, W. K. 2022. Phenotypic Changes of PD-1 and GITR in T Cells Are Associated With Hepatitis B Surface Antigen Seroclearance. J Clin Gastroenterol 56, e31-e37.

      38. Liu, J., Jiang, M., Ma, Z., Dietze, K. K., Zelinskyy, G., Yang, D., Dittmer, U., Schlaak, J. F., Roggendorf, M., Lu, M. 2013. TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+ T cell immunity in vitro. J Immunol 191, 6178-90.

      39. Liu, J., Zhang, E., Ma, Z., Wu, W., Kosinska, A., Zhang, X., Moller, I., Seiz, P., Glebe, D., Wang, B., Yang, D., Lu, M., Roggendorf, M. 2014. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 10, e1003856.

      40. Liu, S., Xu, C., Yang, F., Zong, L., Qin, Y., Gao, Y., Su, Q., Li, T., Li, Y., Xu, Y., Zheng, M. 2022. Natural Killer Cells Induce CD8(+) T Cell Dysfunction via Galectin-9/TIM-3 in Chronic Hepatitis B Virus Infection. Front Immunol 13, 884290.

      41. Liu, X., Li, M., Wang, X., Dang, Z., Jiang, Y., Wang, X., Kong, Y., Yang, Z. 2019. PD-1(+) TIGIT(+) CD8(+) T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular car-cinoma. Cancer Immunol Immunother 68, 2041-2054.

      42. Liu, Y., Meng, X., Wang, C., Zhang, Y., Hua, W. W., Wang, Z. 2022. Interleukin-18 Plays a Positive Feedback Activity to Natural Killer-Like B Cells in Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure. Viral Im-munol 35, 50-59.

      43. Locarnini, S., Hatzakis, A., Chen, D. S., Lok, A. 2015. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol 62, S76-86.

      44. Lok, A. S., Pan, C. Q., Han, S. H., Trinh, H. N., Fessel, W. J., Rodell, T., Massetto, B., Lin, L., Gaggar, A., Subra-manian, G. M., McHutchison, J. G., Ferrari, C., Lee, H., Gordon, S. C., Gane, E. J. 2016. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol 65, 509-16.

      45. Lumley, S. F., McNaughton, A. L., Klenerman, P., Lythgoe, K. A., Matthews, P. C. 2018. Hepatitis B Virus Adap-tation to the CD8+ T Cell Response: Consequences for Host and Pathogen. Front Immunol 9, 1561.

      46. Ma, C. S., Deenick, E. K., Batten, M., Tangye, S. G. 2012. The origins, function, and regulation of T follicular helper cells. J Exp Med 209, 1241-53.

      47. McLane, L. M., Abdel-Hakeem, M. S., Wherry, E. J. 2019. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol 37, 457-495.

      48. Miao, L., Zhang, Z., Ren, Z., Li, Y. 2021. Reactions Related to CAR-T Cell Therapy. Front Immunol 12, 663201.

      49. Michler, T., Kosinska, A. D., Festag, J., Bunse, T., Su, J., Ringelhan, M., Imhof, H., Grimm, D., Steiger, K., Mogler, C., Heikenwalder, M., Michel, M. L., Guzman, C. A., Milstein, S., Sepp-Lorenzino, L., Knolle, P., Protzer, U. 2020. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice. Gastroenterology 158, 1762-1775.e9.

      50. Mohammadizad, H., Shahbazi, M., Hasanjani, R. M., Soltanzadeh-Yamchi, M., Mohammadnia-Afrouzi, M. 2019. TIM-3 as a marker of exhaustion in CD8(+) T cells of active chronic hepatitis B patients. Microb Pathog 128, 323-328.

      51. Mutimer, D., Elsharkawy, A., Hathorn, E., Arunkumar, S. 2022. Hepatitis B e antigen and e antibody in a multi-ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20 years. J Vi-ral Hepat 29, 879-889.

      52. Pal, S., Dey, D., Chakraborty, B. C., Nandi, M., Khatun, M., Banerjee, S., Santra, A., Ghosh, R., Ahammed, S. M., Chowdhury, A., Datta, S. 2022. Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing. Hepatology 76, 759-774.

      53. Pallett, L. J., Gill, U. S., Quaglia, A., Sinclair, L. V., Jover-Cobos, M., Schurich, A., Singh, K. P., Thomas, N., Das, A., Chen, A., Fusai, G., Bertoletti, A., Cantrell, D. A., Kennedy, P. T., Davies, N. A., Haniffa, M., Maini, M. K. 2015. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med 21, 591-600.

      54. Protzer, U., Maini, M. K., Knolle, P. A. 2012. Living in the liver: hepatic infections. Nat Rev Immunol 12, 201-13.

      55. Raziorrouh, B., Schraut, W., Gerlach, T., Nowack, D., Gruner, N. H., Ulsenheimer, A., Zachoval, R., Wachtler, M., Spannagl, M., Haas, J., Diepolder, H. M., Jung, M. C. 2010. The immunoregulatory role of CD244 in chronic hepa-titis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 52, 1934-47.

      56. Rivino, L., Le Bert, N., Gill, U. S., Kunasegaran, K., Cheng, Y., Tan, D. Z., Becht, E., Hansi, N. K., Foster, G. R., Su, T. H., Tseng, T. C., Lim, S. G., Kao, J. H., Newell, E. W., Kennedy, P. T., Bertoletti, A. 2018. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Invest 128, 668-681.

      57. Ronca, V., Wootton, G., Milani, C., Cain, O. 2020. The Immunological Basis of Liver Allograft Rejection. Front Immunol 11, 2155.

      58. Salimzadeh, L., Le Bert, N., Dutertre, C. A., Gill, U. S., Newell, E. W., Frey, C., Hung, M., Novikov, N., Fletcher, S., Kennedy, P. T., Bertoletti, A. 2018. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest 128, 4573-4587.

      59. Schmidt, N. M., Wing, P., Diniz, M. O., Pallett, L. J., Swadling, L., Harris, J. M., Burton, A. R., Jeffery-Smith, A., Zakeri, N., Amin, O. E., Kucykowicz, S., Heemskerk, M. H., Davidson, B., Meyer, T., Grove, J., Stauss, H. J., Pineda-Torra, I., Jolly, C., Jury, E. C., McKeating, J. A., Maini, M. K. 2021. Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. Nat Commun 12, 2814.

      60. Schubert, M. L., Schmitt, M., Wang, L., Ramos, C. A., Jordan, K., Muller-Tidow, C., Dreger, P. 2021. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 32, 34-48.

      61. Schuch, A., Salimi, A. E., Heim, K., Wieland, D., Kiraithe, M. M., Kemming, J., Llewellyn-Lacey, S., Sogukpinar, O., Ni, Y., Urban, S., Zimmermann, P., Nassal, M., Emmerich, F., Price, D. A., Bengsch, B., Luxenburger, H., Neumann-Haefelin, C., Hofmann, M., Thimme, R. 2019. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut 68, 905-915.

      62. Schurich, A., Pallett, L. J., Lubowiecki, M., Singh, H. D., Gill, U. S., Kennedy, P. T., Nastouli, E., Tanwar, S., Rosenberg, W., Maini, M. K. 2013. The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells. PLoS Pathogens 9, e1003208.

      63. Sekine, T., Perez-Potti, A., Nguyen, S., Gorin, J. B., Wu, V. H., Gostick, E., Llewellyn-Lacey, S., Hammer, Q., Falck-Jones, S., Vangeti, S., Yu, M., Smed-Sorensen, A., Gaballa, A., Uhlin, M., Sandberg, J. K., Brander, C., Nowak, P., Goepfert, P. A., Price, D. A., Betts, M. R., Buggert, M. 2020. TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells. Sci Immunol 5.

      64. Shan, F., Somasundaram, A., Bruno, T. C., Workman, C. J., Vignali, D. 2022. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer 8, 944-961.

      65. Shao, X., Ma, J., Jia, S., Yang, L., Wang, W., Jin, Z. 2017. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection. Front Cell Infect Microbiol 7, 472.

      66. Shen, Z., Gao, Z., Gu, C., Wu, J., Wang, J., Zhang, J., Xie, Y., Liu, J. 2021. Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence. Antiviral Res 190, 105076.

      67. Shen, Z., Liu, J., Wu, J., Zhu, Y., Li, G., Wang, J., Luo, M., Deng, Q., Zhang, J., Xie, Y. 2019. IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models. Theranostics 9, 3798-3811.

      68. Su, J., Brunner, L., Ates, O. E., Sacherl, J., Frank, G., Kerth, H. A., Thiele, F., Wiegand, M., Mogler, C., Aguilar, J. C., Knolle, P. A., Collin, N., Kosinska, A. D., Protzer, U. 2023. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models. J Hepatol 78, 717-730.

      69. Tan, A. T., Meng, F., Jin, J., Zhang, J. Y., Wang, S. Y., Shi, L., Shi, M., Li, Y., Xie, Y., Liu, L. M., Zhou, C. B., Chua, A., Ho, Z. Z., Luan, J., Zhao, J., Li, J., Wai, L. E., Koh, S., Wang, T., Bertoletti, A., Wang, F. S. 2022. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC. Hepatol Commun 6, 841-854.

      70. Tang, L., Chen, C., Gao, X., Zhang, W., Yan, X., Zhou, Y., Guo, L., Zheng, X., Wang, W., Yang, F., Liu, G., Sun, J., Hou, J., Li, Y. 2019. Interleukin 21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Chronic HBV Infection. J Infect Dis 219, 750-759.

      71. Thimme, R., Wieland, S., Steiger, C., Ghrayeb, J., Reimann, K. A., Purcell, R. H., Chisari, F. V. 2003. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77, 68-76.

      72. Upadhyay, R., Boiarsky, J. A., Pantsulaia, G., Svensson-Arvelund, J., Lin, M. J., Wroblewska, A., Bhalla, S., Scholler, N., Bot, A., Rossi, J. M., Sadek, N., Parekh, S., Lagana, A., Baccarini, A., Merad, M., Brown, B. D., Brody, J. D. 2021. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discov 11, 599-613.

      73. Wang, D., Fu, B., Shen, X., Guo, C., Liu, Y., Zhang, J., Sun, R., Ye, Y., Li, J., Tian, Z., Wei, H. 2021. Restoration of HBV-specific CD8(+) T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-alpha therapy. Signal Transduct Target Ther 6, 376.

      74. Wang, Q., Pan, W., Liu, Y., Luo, J., Zhu, D., Lu, Y., Feng, X., Yang, X., Dittmer, U., Lu, M., Yang, D., Liu, J. 2018. Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment. Front Immunol 9, 219.

      75. Wang, X., Dong, Q., Li, Q., Li, Y., Zhao, D., Sun, J., Fu, J., Meng, F., Lin, H., Luan, J., Liu, B., Wang, M., Wang, F. S., He, F., Tang, L. 2018. Dysregulated Response of Follicular Helper T Cells to Hepatitis B Surface Antigen Promotes HBV Persistence in Mice and Associates With Outcomes of Patients. Gastroenterology 154, 2222-2236.

      76. Wei, Y. Y., Fan, J., Shan, M. X., Yin, D. D., Wang, L. L., Ye, W., Zhao, W. 2022. TIGIT marks exhausted T cells and serves as a target for immune restoration in patients with chronic HBV infection. Am J Transl Res 14, 942-954.

      77. Wherry, E. J. 2011. T cell exhaustion. Nat Immunol 12, 492-9.

      78. Wherry, E. J., Kurachi, M. 2015. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15, 486-99.

      79. WHO (2023). World health statistics 2023: monitoring health for the SDGs, Sustainable Development Goals. Gene-va, World Health Organization.

      80. Xie, X., Luo, J., Broering, R., Zhu, D., Zhou, W., Lu, M., Zheng, X., Dittmer, U., Yang, D., Liu, J. 2021. HBeAg induces liver sinusoidal endothelial cell activation to promote intrahepatic CD8 T cell immunity and HBV clearance. Cell Mol Immunol 18, 2572-2574.

      81. Xie, X., Luo, J., Zhu, D., Zhou, W., Yang, X., Feng, X., Lu, M., Zheng, X., Dittmer, U., Yang, D., Liu, J. 2022. HBeAg Is Indispensable for Inducing Liver Sinusoidal Endothelial Cell Activation by Hepatitis B Virus. Front Cell Infect Microbiol 12, 797915.

      82. Xiong, S., Zhu, D., Liang, B., Li, M., Pan, W., He, J., Wang, H., Sutter, K., Dittmer, U., Lu, M., Liu, D., Yang, D., Liu, J., Zheng, X. 2021. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss. EBioMedicine 69, 103464.

      83. Xu, J., Zhan, Q., Fan, Y., Yu, Y., Zeng, Z. 2021. Human genetic susceptibility to hepatitis B virus infection. Infect Genet Evol 87, 104663.

      84. Yang, S., Wang, L., Pan, W., Bayer, W., Thoens, C., Heim, K., Dittmer, U., Timm, J., Wang, Q., Yu, Q., Luo, J., Liu, Y., Hofmann, M., Thimme, R., Zhang, X., Chen, H., Wang, H., Feng, X., Yang, X., Lu, Y., Lu, M., Yang, D., Liu, J. 2019. MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance. J Hepatol 71, 685-698.

      85. Yong, Y. K., Saeidi, A., Tan, H. Y., Rosmawati, M., Enstrom, P. F., Batran, R. A., Vasuki, V., Chattopadhyay, I., Murugesan, A., Vignesh, R., Kamarulzaman, A., Rajarajeswaran, J., Ansari, A. W., Vadivelu, J., Ussher, J. E., Velu, V., Larsson, M., Shankar, E. M. 2018. Hyper-Expression of PD-1 Is Associated with the Levels of Exhausted and Dysfunctional Phenotypes of Circulating CD161(++)TCR iValpha7.2(+) Mucosal-Associated Invariant T Cells in Chronic Hepatitis B Virus Infection. Front Immunol 9, 472.

      86. Zhang, W., Luo, S., Li, T., Wang, M., Huang, J., Liao, Q., Liu, B., Rong, X., Li, L., Allain, J. P., Fu, Y., Li, C. 2022. Hepatitis B Virus-Specific Cellular Immunity Contributes to the Outcome of Occult Hepatitis B Virus Infection. Front Microbiol 13, 850665.

      87. Zhao, H., Wang, H., Hu, Y., Xu, D., Yin, C., Han, Q., Zhang, J. 2021. Chitosan Nanovaccines as Efficient Carrier Adjuvant System for IL-12 with Enhanced Protection Against HBV. Int J Nanomedicine 16, 4913-4928.

    • 加载中
    PDF

    Article Metrics

    Article views(1558) PDF downloads(26) Cited by()

    Related
    Proportional views

      Recent advances in understanding T cell activation and exhaustion during HBV infection

        Corresponding author: Ling Fang, 287812165@qq.com
        Corresponding author: Jia Liu, jialiu77@hust.edu.cn
      • a. Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China;
      • b. Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, 430022, China;
      • c. Central Sterile Supply Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
      • Received Date: 04 July 2023
      • Accepted Date: 18 October 2023

      Abstract: Chronic hepatitis B virus (HBV) infection remains a major public health concern globally, and T cell responses are widely believed to play a pivotal role in mediating HBV clearance. Accordingly, research on the characteristics of HBV-specific T cell responses, from activation to exhaustion, has advanced rapidly. Here, we summarize recent developments in characterizing T cell immunity in HBV infection by reviewing basic and clinical research published in the last five years. We provide a comprehensive summary of the mechanisms that induce effective anti-HBV T cell immunity, as well as the latest developments in understanding T cell dysfunction in chronic HBV infection. Furthermore, we briefly discuss current novel treatment strategies aimed at restoring anti-HBV T cell responses.

        HTML

      Reference (87) Relative (20)

      目录

      This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE)

      鄂ICP备05001977号

         

      鄂公网安备 42010602003674号

      Copyright © 2019 Virologica Sinica. All rights reserved

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return